Target family: 3.5.1.- Histone deacetylases (HDACs) (type: enzyme)
Target: histone deacetylase 3

Ligand: vorinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2006)
Primary target: no
Median affinity: 8.300000190734863 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: trichostatin A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: tacedinaline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.260000228881836 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: suprastat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.449999809265137 pIC50
Reference (Journal): Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Published in: J Med Chem

Ligand: scriptaid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.390000343322754 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: romidepsin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: no
Median affinity: 9.819999694824219 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: ricolinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.289999961853027 pIC50
Reference (Journal): Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Published in: Blood

Ligand: RGFP966 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner.
Published in: Proc Natl Acad Sci USA

Ligand: RGFP109 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pKi
Reference (Journal): Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.
Published in: PLoS ONE

Ligand: resminostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Published in: Br J Haematol

Ligand: quisinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.3100004196167 pIC50
Reference (Journal): JNJ-26481585, a novel &quot;second-generation&quot; oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Published in: Clin Cancer Res

Ligand: pracinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pIC50
Reference (Journal): SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Published in: Mol Cancer Ther

Ligand: panobinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 8.399999618530273 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: mocetinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.579999923706055 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: martinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pIC50
Reference (Journal): In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.
Published in: J Med Chem

Ligand: inhibitor M9 [PMID: 38236416] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.309999942779541 pIC50
Reference (Journal): Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality.
Published in: J Med Chem

Ligand: givinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2024)
Primary target: no
Median affinity: 8.520000457763672 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: givinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2024)
Primary target: no
Median affinity: 7.679999828338623 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: fimepinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pIC50
Reference (Journal): Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Published in: Clin Cancer Res

Ligand: entinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.639999866485596 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: entinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: droxinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.769999980926514 pIC50
Reference (Journal): Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.
Published in: Mol Cancer Ther

Ligand: dacinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.380000114440918 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: CUDC-101 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.039999961853027 pIC50
Reference (Journal): Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Published in: J Med Chem

Ligand: compound 30 [PMID: 37057760] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.130000114440918 pIC50
Reference (Journal): Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
Published in: J Med Chem

Ligand: citarinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.340000152587891 pIC50
Reference (Journal): Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Published in: Oncotarget

Ligand: CHR-3996 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Published in: J Med Chem

Ligand: butyric acid (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.050000190734863 pIC50
Reference (Journal): Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Published in: ACS Med Chem Lett

Ligand: BML-281 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
Published in: J Med Chem

Ligand: belinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2014)
Primary target: no
Median affinity: 7.519999980926514 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: belinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2014)
Primary target: no
Median affinity: 8.819999694824219 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: apicidin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: apicidin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.59000015258789 pKi
Reference (Journal): Chemical phylogenetics of histone deacetylases.
Published in: Nat Chem Biol

Ligand: apicidin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pEC50
Reference (Journal): Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Published in: Biochem J

Ligand: ACY-738 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pIC50
Reference (Journal): Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
Published in: Neuropsychopharmacology

Ligand: abexinostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.09000015258789 pIC50
Reference (Journal): CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Published in: Mol Cancer Ther